Menactra
Trials 29
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01867463 | Mar 2013 → Dec 2015 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00874549 | Oct 2007 → Jan 2008 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 28 trials · 1 met primary | ||||||
| Phase 2 | NCT02640404 | Jun → Dec 2016 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01442675 | Sep 2011 → Jun 2012 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 2 | NCT01239043 | Nov 2010 → Apr 2011 | meningococcal meningitis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00505063 | Jul 2007 → Jun 2025 | childhood malignant neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00355121 | Oct 2006 → Jun 2009 | diphtheria, meningococcal meningitis, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00258856 | Jan 2006 → Mar 2007 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00643916 | Dec 2004 → Mar 2006 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00777790 | Feb → Apr 2004 | meningitis, meningococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05298644 | Oct 2022 → Jul 2023 | COVID-19 | Valneva Austria GmbH | Withdrawn | No outcome recorded |
| Phase 312 trials · 2 met primary | ||||||
| Phase 3 | NCT06834100 | Feb → Dec 2025 overdue | meningococcal infection | NPO Petrovax | Recruiting | No outcome recorded |
| Phase 3 | NCT01642589 | Jul 2012 → Jan 2013 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01359449 | May 2011 → Jul 2012 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01086969 | Jun 2010 → Feb 2011 | meningitis, meningococcal infection | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00988884 | Oct 2009 → Feb 2011 | human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT00856297 | Feb 2009 → Nov 2012 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00539032 | Sep 2007 → Aug 2008 | meningitis, meningococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00483574 | May 2007 → Jan 2009 | chickenpox, measles, meningococcal meningitis, mumps infectious disease +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00444951 | Feb 2007 → Feb 2008 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00369824 | Sep 2006 → Nov 2007 | human papilloma virus infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00384397 | Sep 2006 → Aug 2008 | chickenpox, measles, meningococcal meningitis, mumps infectious disease +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00325130 | Apr 2006 → Apr 2007 | diphtheria, meningitis, neoplasm, pertussis +1 | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 46 trials | ||||||
| Phase 4 | NCT06436274 | Oct 2024 → Dec 2026 expected | HIV infectious disease, human papilloma virus infection | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01659996 | Jul 2012 → Nov 2014 | diphtheria, haemophilus meningitis, meningococcal infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01270503 | Dec 2010 → Dec 2013 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00119080 | Aug 2006 → May 2007 | meningitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT00282295 | Jan → Aug 2006 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00777257 | Apr 2005 → Mar 2007 | diphtheria, meningitis, meningococcemia, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 1 | NCT02942277 Comparator | Oct 2016 → Jul 2020 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 1 | NCT02810340 Comparator | Aug 2016 → Oct 2017 | meningococcal infection | PATH | Completed | No outcome recorded |
| Phase 1 | NCT02334462 Comparator | Jan 2015 → Mar 2016 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03917654 Comparator | Apr 2019 → Jul 2021 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03295318 Comparator | Nov 2017 → Aug 2018 | meningococcal meningitis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01165242 Comparator | Aug 2010 → Feb 2011 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT00700713 Comparator | Jun 2008 → Feb 2009 | meningitis, meningococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00700635 Comparator | Jun 2008 → May 2009 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00454909 Comparator | Apr → Oct 2007 | meningococcal infection | GlaxoSmithKline | Completed | Mixed |
| Phase 2/3 | NCT04358731 Comparator | Dec 2019 → Mar 2021 | meningococcal infection | Serum Institute of India Pvt. Ltd. | Completed | Met primary |
| Phase 3 | NCT05794230 Comparator | Mar 2023 → Nov 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04368429 Comparator | May → Nov 2020 | — | Sanofi | Completed | Met primary |
| Phase 3 | NCT03964012 Comparator | Aug 2019 → Feb 2020 | meningococcal meningitis | Serum Institute of India Pvt. Ltd. | Completed | Met primary |
| Phase 3 | NCT02752906 Comparator | Apr → Dec 2016 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00450437 Comparator | Mar → Aug 2007 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT04450498 Comparator | Dec 2020 → Jul 2021 | meningococcal meningitis | Walvax Biotechnology Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT04224311 Comparator | Mar 2020 → Oct 2023 | meningococcal meningitis | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02633787 Background | Dec 2015 → Feb 2016 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 48 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Menactra | “Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly...” NCT00777257 ↗46“This study compares the safety and immunogenicity of the Novartis Vaccines investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, with the licensed...” PMID 19476428 ↗ Jul 2009 “A meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4; Menactra; Sanofi Pasteur Inc, Swiftwater, Pa) was developed to improve...” PMID 16203934 ↗ Oct 2005 “Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.” PMID 21339701 ↗ Nov 2010 “Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects Aged 9 Months to 55 Years in Vietnam” NCT02640404 ↗ “Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine)” NCT00700713 ↗ “Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine)” NCT01659996 ↗ “Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.” NCT05298644 ↗ “Group 2 (n = 40) will receive Menactra® at a dose of 0.5 mL intramuscularly into the deltoid site.” NCT06834100 ↗ “Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.” NCT00384397 ↗ “2 doses of MenACYW conjugate vaccine compared to 2 doses of Menactra® vaccine” NCT05794230 ↗ |
| Known as | MCV-4 | “A phase IV randomized, observer-blind, controlled study compared the safety and immunogenicity of a quadrivalent meningococcal polysaccharide vaccine (MPV-4, MPV ACYW135) and...” PMID 37401618 ↗ Jul 20233“A meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4; Menactra; Sanofi Pasteur Inc, Swiftwater, Pa) was developed to improve...” PMID 16203934 ↗ Oct 2005 “The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or...” PMID 21339701 ↗ Nov 2010 “A new tetravalent (A, C, Y, W-135) meningococcal conjugate vaccine (\[MCV4\], MenactraTM manufactured by Sanofi Pasteur Inc.) has been approved by Food and Drug Administration...” NCT00119080 ↗ |
| Known as | MCV4-DT | “a licensed MCV4 (Menactra®; MCV4-DT [n = 407]).” PMID 32209015 ↗ Mar 2020 |
| Known as | Menactra Vaccine | “Menactra® Vaccine” NCT00539032 ↗ |
| Known as | Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine | “Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly...” NCT00777257 ↗ |
| Known as | TetraMenD | “one or two doses of Menactra® (TetraMenD) administered in children less than 2 years of age” NCT00643916 ↗ |
| Modality | Vaccine | “Menactra® vaccine” NCT00258856 ↗ |
| Route | Intramuscular | “Menactra™ vaccine was administered intramuscularly” NCT00282295 ↗ |